期刊
LABORATORY MEDICINE
卷 53, 期 2, 页码 206-209出版社
OXFORD UNIV PRESS
DOI: 10.1093/labmed/lmab050
关键词
EDTA-induced pseudothrombocytopenia; SARS-CoV-2 virus infection; COVID-19; persisting anti-SARS-CoV-2 IgM/IgG seropositivity; antinucleocapsid antibody; anti-Spike 1 receptor binding domain (anti-S1-RBD); anti-Spike 1 and Spike 2 (anti-S1/S2) IgG test
Platelets play a significant role in vascular complications of COVID-19-related viral coagulopathy, and immune-induced thrombocytopenia has been reported in moderate-to-severe cases. The prognostic role of platelet count in COVID-19 is still controversial, and the presence of EDTA-induced pseudothrombocytopenia in patients even after 9 months post initial infection suggests a possible link to anti-SARS-CoV-2 antibodies.
Platelets have a role in vascular complications of COVID-19-related viral coagulopathy. Although immune-induced thrombocytopenia has been described mostly in moderate-to-severe COVID-19, the prognostic role of platelet count in COVID-19 is still controversial. Pseudothrombocytopenia has been reported to represent COVID-19-associated coagulopathy in critical illness, and transient EDTA-dependent pseudothrombocytopenia lasting less than 3 weeks was described in a patient with severe acute COVID-19 pneumonia. In our case study, EDTA-induced pseudothrombocytopenia was still present at 9 months after an initial SARS-CoV-2 virus infection in an apparently recovered 60 year old man. The persistence of antinucleocapside and antispike antibodies 9 months after the initial infection suggests that EDTA-induced pseudothrombocytopenia may be related to anti-SARS-CoV-2 IgG or IgM antibodies. We should acknowledge the possibility that pseudothrombocytopenia may also appear in some patients after seroconversion after the launch of large-scale vaccination programs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据